Nishadil
Nishadil Ads Nishadil Astrology Nishadil Developers Nishadil Domains Nishadil Drive Nishadil Finance Nishadil Pay Nishadil Weather Nishdil Calendar Rewards
Signup Signin
Washington | 22°C (few clouds)
Topic Feed

SareptaTherapeutics

Showing the latest stories and updates for this topic.
Sarepta's Shares Climb as Critical Safety Study for Elevidys Gene Therapy Kicks Off

Sarepta's Shares Climb as Critical Safety Study for Elevidys Gene Therapy Kicks Off
The Million-Dollar Question: Unpacking the FDA Chief's Gene Therapy Warning

The Million-Dollar Question: Unpacking the FDA Chief's Gene Therapy Warning
The End of an Era: Doug Ingram Prepares to Retire from Sarepta, Elizabeth Barrett Named Successor

The End of an Era: Doug Ingram Prepares to Retire from Sarepta, Elizabeth Barrett Named Successor
A Legal Storm Brews: Sarepta's Groundbreaking Muscular Dystrophy Therapy Faces Renewed Patent Challenge

A Legal Storm Brews: Sarepta's Groundbreaking Muscular Dystrophy Therapy Faces Renewed Patent Challenge
A Vital Step Forward: Sarepta's Duchenne Drug Secures Key Testing Clearance

A Vital Step Forward: Sarepta's Duchenne Drug Secures Key Testing Clearance
The High Stakes Game: Sarepta, Duchenne, and the Edge of Hope

The High Stakes Game: Sarepta, Duchenne, and the Edge of Hope
The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs

The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs
A New Horizon for Duchenne: FDA Approves First Gene Therapy for Life-Threatening Disease in Boys

A New Horizon for Duchenne: FDA Approves First Gene Therapy for Life-Threatening Disease in Boys
Load more..